{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:21:35Z","timestamp":1788322895580,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder primarily caused by autoantibodies against acetylcholine receptors (AChR), leading to muscle weakness. In 2021, efgartigimod was FDA-approved as the first neonatal Fc receptor (FcRn) blocker for generalized MG, reducing pathogenic IgG autoantibodies and improving symptoms. We present a 39-year-old woman with AChR-positive generalized MG and a history of resolved inflammatory myocarditis. Owing to persistent weakness despite intravenous immunoglobulin, she transitioned to efgartigimod. Efgartigimod induced significant neuromuscular improvement, reducing her myasthenia gravis activities of daily living (MG-ADL) score from 9 to 4. However, 3 months later, she developed fatal fulminant heart failure (LVEF 20%\u201325%) without concurrent skeletal muscle weakness. Despite emergency intervention with veno-arterial extracorporeal membrane oxygenation, the patient died after anoxic brain injury. Although efgartigimod effectively reduces pathogenic IgG, it may not adequately suppress cellular or cytokine-mediated inflammation driving MG-associated myocarditis. Clinicians should exercise caution and maintain cardiac monitoring when prescribing FcRn blockers to patients with a history of myocardial involvement.<\/jats:p>","DOI":"10.1097\/cnd.0000000000000571","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:00:31Z","timestamp":1788321631000},"page":"53-56","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Fatal Myocarditis Relapse in a Patient with Myasthenia Gravis Treated with Efgartigimod Alfa: A Case Report"],"prefix":"10.1097","volume":"28","author":[{"given":"Tal","family":"Friedman Korn","sequence":"first","affiliation":[{"name":"Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-4211","authenticated-orcid":false,"given":"Omri","family":"Zveik-Lavi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ekstein","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Durst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batla","family":"Falah","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Foundation, NYC, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gotkine","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"103875","DOI":"10.1016\/j.autrev.2025.103875","article-title":"Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells","volume":"24","author":"Man\u00e9-Damas","year":"2025","journal-title":"Autoimmun Rev"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00415-022-11485-1","article-title":"Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis","volume":"270","author":"Kim","year":"2023","journal-title":"J Neurol"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti\u2010 K v1.4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur J Neurol"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in Myasthenia Gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2016.07.001","article-title":"Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients","volume":"298","author":"Hong","year":"2016","journal-title":"J Neuroimmunology"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-agrin-and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"123440","DOI":"10.1016\/j.jns.2025.123440","article-title":"The mortality of myasthenia gravis with myocarditis: a single-center retrospective study","volume":"471","author":"Zhang","year":"2025","journal-title":"J Neurol Sci"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"R12-20260902","first-page":"223","article-title":"Effect of follicular T helper and T helper 17 cells-related molecules on disease severity in patients with Myasthenia gravis","volume":"87","author":"Arslan","year":"2024","journal-title":"Eur Neurol"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"102800","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnen\/nly041","article-title":"Giant cell polymyositis and Myocarditis in a patient with Thymoma and Myasthenia gravis: a postviral autoimmune process?","volume":"77","author":"Priemer","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/CIRCRESAHA.124.323816","article-title":"Autoimmune myocarditis, old dogs and new tricks","volume":"134","author":"Won","year":"2024","journal-title":"Circ Res"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00795-022-00340-x","article-title":"Pathological features of biopsied myocardium in patients clinically diagnosed with peripartum cardiomyopathy","volume":"56","author":"Kawano","year":"2023","journal-title":"Med Mol Morphol"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of Acute Myocarditis: a review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1196\/annals.1321.009","article-title":"Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies","volume":"1024","author":"Franchimont","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2022.09.010","article-title":"Azathioprine therapy induces selective NK cell depletion and IFN-\u03b3 deficiency predisposing to herpesvirus reactivation","volume":"151","author":"Ingelfinger","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2024.01.025","article-title":"Assessing the comparative efficacy of plasmapheresis and intravenous immunoglobulin in myasthenia gravis treatment: a systematic review and meta-analysis","volume":"121","author":"Ghimire","year":"2024","journal-title":"J Clin Neurosci"},{"key":"R22-20260902","first-page":"1","article-title":"Immunoglobulin for myasthenia gravis","volume":"2025","author":"Manolopoulos","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbrc.2019.11.169","article-title":"Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to suppress T cell receptor signaling","volume":"522","author":"Hori","year":"2020","journal-title":"Biochem Biophysical Res Commun"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1179\/1743132815Y.0000000017","article-title":"Safety of intravenous immunoglobulin and plasma exchange in critically ill patients","volume":"37","author":"Clark","year":"2015","journal-title":"Neurol Res"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CND.0000000000000571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:00:35Z","timestamp":1788321635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CND.0000000000000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000571","relation":{},"ISSN":["1522-0443","1537-1611"],"issn-type":[{"value":"1522-0443","type":"print"},{"value":"1537-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}